Mutual Fund Insights: Rydex Biotechnology Inv Fund (RYOIX)

In-depth Analysis of Rydex Biotechnology Inv Fund (RYOIX)

3 months 6 months 1 year 3 year 5 year

See Rydex Biotechnology Inv Fund (RYOIX) performance details as of January 31, 2010

  

Last Trade: $27.72 on 3/12/2010, Change: -0.11 (-0.4%)

  

Fund Manager - Michael P. Byrum

Fund Manager Tenure: 12.0 years   [Similar Funds: RYOAX ]
Fundmojo Fund Grade: B (Score: 0.69)     (What does this score mean?)

Byrum is president and CIO of Rydex Investments, his employer since its foundation in 1993. He has ultimate responsibility for the management of the funds. He was named the president of Rydex Investments in 2004 and has served as chief investment officer since 2003.Prior to joining Rydex Investments, Mr. Byrum worked for Money Management Associates, the investment adviser for Rushmore Funds, Inc. Byrum holds the Charted Financial Analyst designation.  Get more insights on Michael P. Byrum

  

 What we like about Rydex Biotechnology Inv Fund (RYOIX)

Data for Rydex Biotechnology Inv Fund (RYOIX) as of January 31, 2010

• Rydex Biotechnology Inv Fund (RYOIX) management has been with Rydex Biotechnology Inv Fund for 12.0 years
• Rydex Biotechnology Inv Fund (RYOIX) has good short-term performance (1-year return 25.06% vs 24.07% Health category average)
• Rydex Biotechnology Inv Fund (RYOIX) has good mid-term performance (3-year return 4.22% vs -0.24% Health category average)
• Rydex Biotechnology Inv Fund (RYOIX) has good Long-term performance (5-year return 6.02% vs 4.22% Health category average)
• Rydex Biotechnology Inv Fund (RYOIX) has a lower management fee than its Health average: 1.38% vs 1.91%
• Rydex Biotechnology Inv Fund (RYOIX) is a true no-load fund as it has no load and no 12b1 promotion, distributions, marketing expenses

  

 What we are cautious about Rydex Biotechnology Inv Fund (RYOIX)

Data for Rydex Biotechnology Inv Fund (RYOIX) as of January 31, 2010

• Rydex Biotechnology Inv Fund is a focused fund with 67.00% of the portfolio on top 10 securities. This tends to produce more volatility compared to a diversified fund. See fund top 10 holdings.
• Rydex Biotechnology Inv Fund (RYOIX) ratio of up-years vs down years can be improved
• Rydex Biotechnology Inv Fund (RYOIX) has a Morningstar rating of 3 and below
• Rydex Biotechnology Inv Fund (RYOIX) is more volatile than its peers as it has a 3-year Standard Deviation of 23.48 that is higher than category average of 18.84

See Rydex Biotechnology Inv Fund (RYOIX) performance details as of January 31, 2010

  

  

Interested in other top mutual funds in similar Health category?

Below are some additional Health mutual funds generated out of our database

• Fidelity Select Pharmaceuticals (FPHAX)    [ Compare with Rydex Biotechnology Inv Fund (RYOIX) ]
• Jennison Health Sciences Z (PHSZX)    [ Compare with Rydex Biotechnology Inv Fund (RYOIX) ]
• BlackRock Health Sciences Ops Inv A (SHSAX)    [ Compare with Rydex Biotechnology Inv Fund (RYOIX) ]
• See top fund managers for Health Category Funds
• Browse other funds in Health Category

  

Rydex Biotechnology Inv Fund (RYOIX) Net Asset

Track net asset change of Rydex Biotechnology Inv fund (RYOIX)

Date	Net Asset
01/2010	$66.70M
11/2009	$45.68M
10/2009	$40.91M

More historic net asset information on Rydex Biotechnology Inv Fund (RYOIX)

  

Rydex Biotechnology Inv Fund (RYOIX) Portfolio Allocation

Track portfolio allocation change of Rydex Biotechnology Inv fund (RYOIX)

Date	Cash	Stock	Bond	Other
11/2009	0.77%	99.23%	0%	0%
09/2009	0.22%	99.78%	0%	0%
08/2009	0.48%	99.52%	0%	0%

Click here to see more historic asset allocation information on Rydex Biotechnology Inv Fund (RYOIX)

  

Most Recent Top 10 Holdings in Rydex Biotechnology Inv Fund (RYOIX)

Discover what Rydex Biotechnology Inv Fund (RYOIX) manager is buying

30-Nov-09 Amgen Inc. [13.1%] Gilead Sciences, Inc. [11.46%] Celgene Corporation [8.94%] Biogen Idec Inc [6.43%] Genzyme Corporation [6.33%] Human Genome Sciences, Inc. [5.38%] Vertex Pharmaceuticals Incorpor [5.29%] Cephalon, Inc. [4.68%] Dendreon Corporation [3.77%] Alexion Pharmaceuticals, Inc. [3.16%]

30-Sep-09 Amgen Inc. [9.99%] Gilead Sciences, Inc. [8.05%] Celgene Corporation [6.95%] Genzyme Corporation [5.05%] Biogen Idec Inc [4.99%] Vertex Pharmaceuticals Incorpor [3.43%] Cephalon, Inc. [2.72%] Alexion Pharmaceuticals, Inc. [2.58%] Human Genome Sciences, Inc. [2.47%] Dendreon Corporation [2.46%]

31-Aug-09 Amgen Inc. [9.78%] Gilead Sciences, Inc. [7.69%] Celgene Corporation [6.4%] Genzyme Corporation [4.9%] Biogen Idec Inc [4.89%] Vertex Pharmaceuticals Incorpor [3.34%] Cephalon, Inc. [2.62%] Alexion Pharmaceuticals, Inc. [2.58%] Human Genome Sciences, Inc. [2.56%] [2.46%]

Click here for Stock Holding Change Map in Rydex Biotechnology Inv Fund (RYOIX)

  

Related books and products to Rydex Biotechnology Inv Fund (RYOIX)

  

Latest News on Rydex Biotechnology Inv (RYOIX)

See what is happening with Rydex Biotechnology Inv Fund (RYOIX)

The Zacks Mutual Fund Rank Reveals Its Top 5 Health Care Funds: Franklin Biotechnology Discovery A, ICON Healthcare, Manning & Napier Life Sciences, Rydex Biotechnology and Fidelity Select Medical Equipment & Systems (Zacks.com) See more news on Rydex Biotechnology Inv Fund (RYOIX)

 

Books and Resources

 

 

See more information on Rydex Biotechnology Inv Fund (RYOIX)

• Rydex Biotechnology Inv Fund Insights
• Rydex Biotechnology Inv Fund Performance Data
• Rydex Biotechnology Inv Fund News
• Rydex Biotechnology Inv Fund Score Explaination
• Rydex Biotechnology Inv Fund Manager Information
• Historic Rydex Biotechnology Inv Fund Asset Allocation Report
• Historic Rydex Biotechnology Inv Fund Top 10 Holding Tracking
• Historic Rydex Biotechnology Inv Fund Asset Under Management Tracking